Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

Company Profile

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 89 2153 9035

Website: atai.com

Address:

Wallstraße 16, Berlin, Germany

McGuireTO Aug. 27 at 1:41 AM

$ATAI $CMPS $CYBN $MNMD - Click to watch the free analysis video. The Gilgamesh news confirmation saw a bullish sector-wide push into a little blow off top and a pretty steep selloff of double digit percentages. What can we expect from the sector over the rest of the week? We learned a lot today and tomorrow will be just as valuable, but here are the most likely scenarios I'm seeing based on how bulls shook off the hangover in today's trading session. I post regular technical analysis of the psychedelic sector and other. key charts. Be sure to like and follow to not miss an update! https://www.tradingview.com/chart/CMPS/1zeVS8aj-Psychedelic-Bears-Smack-down-what-happens-next/

0 · Reply

McGuireTO Aug. 26 at 8:40 PM

$ATAI $MNMD $CMPS $CYBN I learned a lot from today's price action after yesterday's gross profit taking candles and will be posting video analysis later this evening. Be sure to like and follow to not miss an important video at a key precipice in the charts for the psychedelic sector!

1 · Reply

DriuxP Aug. 26 at 8:36 PM

$ATAI $CMPS gotta admit, I did not see today being green after yesterday's reversal candles on these two. Cautiously optimistic about the rest of the week....

1 · Reply

matrixtrade123 Aug. 26 at 7:40 PM

$ATAI this is my Biggest Position and it is slowly becoming what I like to call A STALWART !

0 · Reply

PreGigs Aug. 26 at 3:55 PM

$ATAI This is perfect for getting to 10k shares!

1 · Reply

brunoq14 Aug. 26 at 2:33 PM

$ATAI Let's finish the merger and get on to Phase 3 with the lead drug.

1 · Reply

PsychedStocks Aug. 26 at 2:15 PM

$CYBN $CMPS $ATAI $MNMD $SPY Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder https://ir.cybin.com/investors/news/news-details/2025/Cybin-Receives-Australian-Approval-for-EMBRACE-a-Multinational-Pivotal-Study-Evaluating-CYB003-for-the-Adjunctive-Treatment-of-Major-Depressive-Disorder/default.aspx

2 · Reply

Cat666 Aug. 26 at 2:02 PM

$ATAI do I hear $5?

1 · Reply

twiggs462 Aug. 26 at 1:52 PM

$ABBV with Abbvie buying out Gilgamesh. $MNMD & $ATAI are on watch for M&A. The future is psychedelic.

0 · Reply

FLNY Aug. 26 at 1:50 PM

$ATAI Doubled my position today. (LET'S GO)

1 · Reply

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 10:58 AM EDT - 4 weeks ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 8:13 AM EDT - 4 weeks ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Jul 25, 2025, 4:16 PM EDT - 4 weeks ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:05 PM EDT - 4 weeks ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 2, 2025, 2:29 PM EDT - 7 weeks ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 1, 2025, 9:28 AM EDT - 2 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 6:05 AM EDT - 2 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:00 AM EDT - 2 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jun 2, 2025, 6:00 AM EDT - 3 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

May 29, 2025, 8:30 AM EDT - 3 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

May 20, 2025, 7:00 AM EDT - 3 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 14, 2025, 7:00 AM EDT - 3 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 13, 2025, 7:01 AM EDT - 3 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Mar 11, 2025, 7:00 AM EDT - 6 months ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Feb 27, 2025, 12:45 PM EST - 6 months ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 24, 2025, 4:10 PM EST - 6 months ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 7:00 AM EST - 6 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Feb 12, 2025, 10:47 PM EST - 6 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Feb 12, 2025, 4:01 PM EST - 6 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Jan 29, 2025, 11:57 AM EST - 7 months ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 10, 2025, 7:00 AM EST - 8 months ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Oct 2, 2024, 9:21 AM EDT - 11 months ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS CYBN MNMD

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Mar 28, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 27, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Mar 4, 2024, 8:00 AM EST - 1 year ago

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Feb 28, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

Jan 4, 2024, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Nov 29, 2023, 6:55 PM EST - 1 year ago

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value

Nov 14, 2023, 7:03 AM EST - 1 year ago

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Oct 6, 2023, 4:05 PM EDT - 2 years ago

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 2, 2023, 4:13 PM EDT - 2 years ago

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Sep 14, 2023, 8:02 AM EDT - 2 years ago

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 6, 2023, 4:01 PM EDT - 2 years ago

atai Life Sciences to Participate in Upcoming September Investor Conferences

Sep 1, 2023, 7:02 PM EDT - 2 years ago

Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies

Aug 10, 2023, 6:59 AM EDT - 2 years ago

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Aug 8, 2023, 4:02 PM EDT - 2 years ago

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

McGuireTO Aug. 27 at 1:41 AM

0 · Reply

McGuireTO Aug. 26 at 8:40 PM

1 · Reply

DriuxP Aug. 26 at 8:36 PM

$ATAI $CMPS gotta admit, I did not see today being green after yesterday's reversal candles on these two. Cautiously optimistic about the rest of the week....

1 · Reply

matrixtrade123 Aug. 26 at 7:40 PM

$ATAI this is my Biggest Position and it is slowly becoming what I like to call A STALWART !

0 · Reply

PreGigs Aug. 26 at 3:55 PM

$ATAI This is perfect for getting to 10k shares!

1 · Reply

brunoq14 Aug. 26 at 2:33 PM

$ATAI Let's finish the merger and get on to Phase 3 with the lead drug.

1 · Reply

PsychedStocks Aug. 26 at 2:15 PM

2 · Reply

Cat666 Aug. 26 at 2:02 PM

$ATAI do I hear $5?

1 · Reply

twiggs462 Aug. 26 at 1:52 PM

$ABBV with Abbvie buying out Gilgamesh. $MNMD & $ATAI are on watch for M&A. The future is psychedelic.

0 · Reply

FLNY Aug. 26 at 1:50 PM

$ATAI Doubled my position today. (LET'S GO)

1 · Reply

Garner757 Aug. 26 at 1:09 PM

$ATAI New preclinical science continues to strengthen the psilocybin–anti-aging narrative, particularly around telomere preservation, oxidative stress reduction, and improved survival in aged mice.

1 · Reply

Insayn Aug. 26 at 7:49 AM

$ATAI Keep in mind that ATAI’s CEO just had performance-based stock options vest — but here’s the key: A large block (650,794 options) can only be exercised at $5.68/share. That means it’s directly in the CEO’s interest for the stock to trade above $5.68 — no gain below that. His upside = our upside. This aligns management with shareholders. If ATAI breaks past $5.68, both retail and leadership win together. ATAI is the next $PLTR in the psychedelic Sector!

1 · Reply

RSINVESTOR37 Aug. 26 at 7:05 AM

$ATAI I’m ansious to see how much this thing can go up with BPL003 FDA approval (they can do it IMO)

0 · Reply

DriuxP Aug. 26 at 6:03 AM

$ATAI $CMPS gnarly candles today, folks.

0 · Reply

Jbgs Aug. 26 at 5:37 AM

$ATAI $MNMD $CMPS https://stocktwits.com/news-articles/markets/equity/abbvie-to-acquire-gilgamesh-lead-candidate-for-up-to-1.2-billion/chssYI7Rd1u

0 · Reply

jattboy Aug. 26 at 12:53 AM

$ATAI the after hours held up well

0 · Reply

BioBum Aug. 26 at 12:32 AM

$ATAI 1 billion market cap, no revenue *fart noise*

1 · Reply

jattboy Aug. 25 at 10:52 PM

$ATAI 6 dollars sep , 10 dollars end of year !

1 · Reply

matrixtrade123 Aug. 25 at 8:37 PM

$ATAI __ so we all will be guessing and nobody really knows but ..... I believe anyone that can hold 1 year, 2 years or 3 years plus will make much more then $4.74?

0 · Reply

Fede_Tech Aug. 25 at 8:13 PM

$ATAI come on! I want a pullback please! Need to load a final portion to my position before it goes 10x.

3 · Reply

Cat666 Aug. 25 at 8:10 PM

$ATAI The growing trend in healthcare is one that recognizes mental health as a vital part of overall health. $UNH is actively expanding its focus on behavioral health, one of the most rapidly growing areas in today’s care world as reported.

0 · Reply

McGuireTO Aug. 25 at 7:51 PM

$ATAI CMPS $MNMD these are really gross profit taking daily candle wicks. Hourly bull flags are completely off the table. Going to have to be cautious of this headline being a temporary climax in the sector

1 · Reply

Market Cap	1.02B
Revenue (ttm)	310,000.00
Net Income (ttm)	-149.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48,151.61%
Debt to Equity Ratio	0.00

Volume	8,123,700
Avg Vol	6,745,950
Day's Range	N/A - N/A
Shares Out	214.34M
Stochastic %K	71%
Beta	1.54
Analysts	Strong Sell
Price Target	$10.50